Genmab — November 2020

DevOp

Det er altså svært at være utilfreds med, selv om det har været en møgdag på kontoret ellers...

Bulder

Jo, det har vi vidst siden E L hackede SITC for længe siden. Vi får opdaterede data på onsdag med posteren.

DevOp

u r so right, det havde jeg glemt alt om. Så bliver det svært at vente til onsdag.

E_L

haha, i don't have any hacking skills -unfortunately- but I think it is a great idea! @Helge; can you hire a hacker please

Helge_LarsenPI-redaktør

E L ..One more?

E_L

GeorgeBest

Genmab presented dose escalation data for its DuoBody-PD-L1x4-1BB in 61 patients with advanced solid tumours at SITC today with six months of follow up. Early data is encouraging with an 11-33% ORR across TNBC https://twitter.com/semodough/status/1325984229063192576?s=21

Helge_LarsenPI-redaktør

God morgen.

Helge_LarsenPI-redaktør

Asien: Generelle stigninger på positivt vaccinehåb - NY
https://www.proinvestor.com/investornyt/669448/asien-generelle-stigninger-pa-positivt-vaccinehab-ny

Helge_LarsenPI-redaktør

Tirsdagens aviser med Tryg, Carlsberg og https://www.proinvestor.com/investornyt/669447/tirsdagens-aviser-med-tryg-
carlsberg-og-nnit

Helge_LarsenPI-redaktør

Aktier/tendens: Ørsted kan tage fokus efter løftet anbefalinghttps://www.proinvestor.com/investornyt/669456/aktier-tendens-orsted-

E_L

BioNTech SEC filings GEN1046
; you can choose if you want ot download it or just view it in your browser by clicking html https://investors.biontech.de/sec-filings/sec-filing/6-k/0001564590-20-052594

E_L

cut off date Aug31

E_L

Data cut-off for Efficacy September 29 I see

E_L

Disease control was achieved in 65.6% of patients, including
partial responses in triple-negative breast cancer (n=1), ovarian
cancer (n=1), and ICI-pretreated NSCLC (n=2).

E_L

Of six patients with NSCLC, all of whom
had received prior immune checkpoint
inhibitor (ICI) therapy, two achieved
unconfirmed PR, two maintained SD, and
two experienced progressive disease

E_L

Expansion cohort
● As of October 12, 2020, 24 patients were enrolled in expansion cohort 1, which includes patients with
NSCLC with progression on or after ICI therapy (Figure 8).
– 12 patients had post-baseline scans; six patients continued treatment with GEN1046, six patients
discontinued.
– Preliminary efficacy in 12 patients who could be objectively assessed showed two patients who
achieved confirmed PR, one with unconfirmed PR, and four patients with SD.

E_L

So it seems they start with NSCLC in the expansian cohorts? Note there where only 6 patients in the escalation cohort, they already put 24 in the expansian as of Oct 12

AaBforever

Seems that the market down like it.

AaBforever

don´t